Experts review a preclinical study of the anti-HER3 monoclonal antibody seribantumab, used in cell lines and mouse models of solid tumors.
Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions
Thoracic oncologists discuss key takeaways and potential translational relevance of seribantumab based on a recent publication by Igor Odintsov, MD, and colleagues.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies
2
Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer
3
Precision Medicine and the “Slow Death” of Transplant in Lymphoma
4
135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study
5